1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Nicox SA.
  6. News
  7. Summary
    COX   FR0013018124

NICOX SA.

(COX)
  Report
Real-time Euronext Paris  -  05/25 11:35:28 am EDT
1.766 EUR   -1.89%
05/16Ophthalmology Group Nicox Appoints New CEO, Chairman
MT
05/16Nicox Announces a New Governance Structure
GL
05/16Nicox Announces a New Governance Structure
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Nicox Appoints Novartis Executive as Chief Scientific Officer

12/13/2021 | 04:25am EDT


© MT Newswires 2021
Stocks mentioned in the article
ChangeLast1st jan.
NICOX SA. -1.89% 1.766 Real-time Quote.-29.55%
NOVARTIS AG 0.16% 87.82 Delayed Quote.9.22%
All news about NICOX SA.
05/16Ophthalmology Group Nicox Appoints New CEO, Chairman
MT
05/16Nicox Announces a New Governance Structure
GL
05/16Nicox Announces a New Governance Structure
AQ
05/16Nicox S.A. Announces Executive Changes
CI
05/04NICOX : 2022 Ordinary Shareholder Meeting
GL
05/04NICOX : 2022 Ordinary Shareholder Meeting
AQ
05/02NICOX AT ARVO 2022 : Presentation of clinical Phase 2 results on NCX 4251 and new non-clin..
GL
05/02NICOX AT ARVO 2022 : Presentation of clinical Phase 2 results on NCX 4251 and new non-clin..
AQ
04/28Nicox Reports 2021 Financial Results and First Quarter 2022 Financial Highlights and Pr..
AQ
04/11Nicox's NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma
AQ
More news
Financials
Sales 2022 9,03 M 9,64 M 9,64 M
Net income 2022 -20,3 M -21,7 M -21,7 M
Net cash 2022 2,49 M 2,66 M 2,66 M
P/E ratio 2022 -3,83x
Yield 2022 -
Capitalization 76,3 M 81,5 M 81,5 M
EV / Sales 2022 8,18x
EV / Sales 2023 6,60x
Nbr of Employees 33
Free-Float 89,6%
Chart NICOX SA.
Duration : Period :
Nicox SA. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NICOX SA.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 1,80 €
Average target price 11,50 €
Spread / Average Target 539%
EPS Revisions
Managers and Directors
Michele Garufi Chairman & Chief Executive Officer
Sandrine Gestin Vice President-Finance
José Boyer Head-Research & Development
Doug Hubatsch Chief Scientific Officer
Jean-François Labbé Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NICOX SA.-29.55%83
MERCK KGAA-22.86%81 684
KYOWA KIRIN CO. LTD.-12.79%11 611
SK BIOPHARMACEUTICALS CO., LTD.-12.04%5 298
YUHAN CORPORATION-4.83%3 181
BETTA PHARMACEUTICALS CO., LTD.-44.12%2 785